These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30609441)

  • 41. Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation.
    Lim S; Kim PJ; Baek C; Kim TH; Koh YS; Park HJ; Kim HY; Chang K; Chung WS; Seung KB
    Clin Drug Investig; 2015 Dec; 35(12):833-42. PubMed ID: 26507618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial.
    Kim SH; Sung JH; Shin J; Lee HJ; Lee HS; Cho DK; Lim SW
    Curr Med Res Opin; 2015 Mar; 31(3):449-57. PubMed ID: 25586295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    Gurbel PA; Erlinge D; Ohman EM; Neely B; Neely M; Goodman SG; Huber K; Chan MY; Cornel JH; Brown E; Zhou C; Jakubowski JA; White HD; Fox KA; Prabhakaran D; Armstrong PW; Tantry US; Roe MT;
    JAMA; 2012 Nov; 308(17):1785-94. PubMed ID: 23117779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrel in Japanese patients.
    Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Wakabayashi S; Hanaoka H; Kobayashi Y
    J Cardiol; 2017 May; 69(5):752-755. PubMed ID: 27567173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity.
    Alexopoulos D; Panagiotou A; Xanthopoulou I; Komninakis D; Kassimis G; Davlouros P; Fourtounas C; Goumenos D
    J Thromb Haemost; 2011 Dec; 9(12):2379-85. PubMed ID: 21985070
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal timing of clopidogrel discontinuation in Japanese patients: platelet aggregation test using the VerifyNow® system.
    Takiuchi H; Tanemoto K
    Gen Thorac Cardiovasc Surg; 2015 Nov; 63(11):601-6. PubMed ID: 26298730
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.
    Sakr HI; Alamri HS; Almoghairi AM; Alkhudair AA; AlMasood AS
    Saudi Med J; 2016 Feb; 37(2):166-72. PubMed ID: 26837400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention.
    Mangiacapra F; De Bruyne B; Muller O; Trana C; Ntalianis A; Bartunek J; Heyndrickx G; Di Sciascio G; Wijns W; Barbato E
    JACC Cardiovasc Interv; 2010 Jan; 3(1):35-40. PubMed ID: 20129566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China.
    Lv HH; Wu S; Liu X; Yang XL; Xu JF; Guan YT; Dong Q; Zheng SL; Jiang JM; Li SX; Luo Z; Li L; An LX; Han Y
    Neurol Sci; 2016 Feb; 37(2):277-82. PubMed ID: 26520845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
    Ueno T; Koiwaya H; Sasaki KI; Katsuki Y; Katsuda Y; Murasato Y; Shimamatsu J; Umeji K; Otsuka Y; Kawasaki T; Shibata Y; Fukumoto Y
    Cardiovasc Interv Ther; 2017 Oct; 32(4):341-350. PubMed ID: 27488859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
    Clavijo LC; Maya J; Carlson G; Angiolillo DJ; Teng R; Caplan R; Price MJ
    Cardiovasc Revasc Med; 2015 Dec; 16(8):450-4. PubMed ID: 26440227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
    Youn YN; Yi G; Lee S; Joo HC; Yoo KJ
    Am Heart J; 2014 Jun; 167(6):818-25. PubMed ID: 24890530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
    Cubero Gómez JM; Acosta Martínez J; Mendias Benítez C; Díaz De La Llera LS; Fernández-Quero M; Guisado Rasco A; Villa Gil-Ortega M; Sánchez González Á
    Acta Cardiol; 2015 Dec; 70(6):728-34. PubMed ID: 26717223
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of initial clinical presentation on clopidogrel low response.
    Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM; Lemesle G
    Arch Cardiovasc Dis; 2013 Nov; 106(11):593-600. PubMed ID: 24070598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
    Mega JL; Hochholzer W; Frelinger AL; Kluk MJ; Angiolillo DJ; Kereiakes DJ; Isserman S; Rogers WJ; Ruff CT; Contant C; Pencina MJ; Scirica BM; Longtine JA; Michelson AD; Sabatine MS
    JAMA; 2011 Nov; 306(20):2221-8. PubMed ID: 22088980
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
    Choi KN; Jin HY; Shin HC; Park YA; Seo JS; Jang JS; Yang TH; Kim DK; Kim DS
    Am J Cardiol; 2017 Jul; 120(2):201-206. PubMed ID: 28554486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
    Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Desai B; Tello-Montoliu A; Rollini F; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):42-9. PubMed ID: 22431415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate.
    Seo KW; Tahk SJ; Yang HM; Yoon MH; Shin JH; Choi SY; Lim HS; Hwang GS; Choi BJ; Park JS; Shin JS; Lee YH; Choi YW; Park SJ; Jin XJ
    Clin Ther; 2014 Nov; 36(11):1588-94. PubMed ID: 25218311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.